Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H10N4O5 |
Molecular Weight | 302.2423 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+](=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)[N+]([O-])=O)C=C1
InChI
InChIKey=JEZZOKXIXNSKQD-UHFFFAOYSA-N
InChI=1S/C13H10N4O5/c18-13(14-9-1-5-11(6-2-9)16(19)20)15-10-3-7-12(8-4-10)17(21)22/h1-8H,(H2,14,15,18)
Molecular Formula | C13H10N4O5 |
Molecular Weight | 302.2423 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.fda.gov/OHRMS/DOCKETS/98fr/140339fi.pdfCurator's Comment: description was created based on several sources, including
https://www.drugs.com/vet/nicarb-25.html | https://www.drugs.com/vet/nicarb-can.html | https://www.ncbi.nlm.nih.gov/pubmed/1886867 | https://www.ncbi.nlm.nih.gov/pubmed/13843719
Sources: https://www.fda.gov/OHRMS/DOCKETS/98fr/140339fi.pdf
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/vet/nicarb-25.html | https://www.drugs.com/vet/nicarb-can.html | https://www.ncbi.nlm.nih.gov/pubmed/1886867 | https://www.ncbi.nlm.nih.gov/pubmed/13843719
Nicarbazin, a complex of two compounds, 4,4'-dinitrocarbanilide (DNC) and 4,6-dimethyl-2-pyrimidinol (HDP) is an effective drug for preventing intestinal and caecal coccidiosis in poultry. It is used for prevention rather than the treatment of disease. Nicarbazin was the first agent with “broad‐spectrum” activity against Eimeria spp. of chickens. Nicarbazin is used as a single agent or in combination with polyether antibiotics (narasin, or maduramicin), roxarsone, or antibiotics (lincomycin, bacitracin, flavomycin) for prevention and control of coccidiosis caused by Eimeria spp. (all relevant species) in broiler chickens. Nicarbazin can cause increased sensitivity to heat stress, which may result in growth depression and even mortality in broilers; death may be due to cell degeneration processes in liver and kidneys; at the recommended dose, the drug causes occasionally toxic effects in laying hens like reduced hatchability and interruption of egg-laying. Nicarbazin interferes with the formation of the vitelline membrane, separating the egg yolk and egg white. The exact mode of action is unknown, although it is thought nicarbazin interferes with cholesterol metabolism in the formation of the membrane.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0008203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13843719 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | NICARB Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.fda.gov/OHRMS/DOCKETS/98fr/140339fi.pdf
Nicarbazin is added to chicken feed at a concentration of 113.5 g/ton as an aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E, necatrix, and E. brunetti) coccidiosis.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1886867
Fibroblasts were obtained by collagenase digestion from chicken skin and cultured. The cultured cells were incubated with various concentrations of nicarbazin (up to 1nM), and [3H]proline incorporation was evaluated in collagenase-digestible (representing mostly collagen) and nondigestible proteins exported by the cells into the medium.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:55:36 GMT 2023
by
admin
on
Fri Dec 15 18:55:36 GMT 2023
|
Record UNII |
9IDD210E75
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9IDD210E75
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY | |||
|
1546355
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY | RxNorm | ||
|
9IDD210E75
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY | |||
|
C039493
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY | |||
|
DTXSID0043761
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY | |||
|
209-607-7
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY | |||
|
101086
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY | |||
|
9509
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY | |||
|
m4574
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
587-90-6
Created by
admin on Fri Dec 15 18:55:36 GMT 2023 , Edited by admin on Fri Dec 15 18:55:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |